Ciongoli Gregory Austin — SEC Form 4 filings
SEC reporting owner CIK 2023732. 5 Form 4 filings on record with FilingPulse; latest filed 2026-08-27.
Transaction summary — filings shown
Covers all 5 filings on record, filed 2025-05-16 to 2026-08-27. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 1 filing — 102,603 shares, $949,381 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 9.
- Largest priced transaction: purchase of 53,407 shares @ $9.36 ($499,676) in REGENXBIO Inc., filed 2026-08-27.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| REGENXBIO Inc. (RGNX) | Director | 1 | 2 legs · 102,603 sh · $949,381 | — | 2 |
| Zymeworks Inc. (ZYME) | Director | 2 | — | — | 4 |
| Atara Biotherapeutics, Inc. (ATRA) | Director, 10% owner | 2 | — | — | 3 |
Form 4 filings — Ciongoli Gregory Austin
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-27 | 4 | REGENXBIO Inc. (RGNX) | Grant/award (A): 15,432 @ $0 · Purchase (P): 49,196 @ $9.14 · Purchase (P): 53,407 @ $9.36 · Grant/award (A): 69,609 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Grant/award (A): 12,000 @ $0 | EDGAR |
| 2026-01-12 | 4 | Zymeworks Inc. (ZYME) | Grant/award (A): 11,500 (derivative) @ $0 · Grant/award (A): 7,700 (derivative) @ $0 | EDGAR |
| 2025-08-12 | 4 | Zymeworks Inc. (ZYME) | Grant/award (A): 415,000 @ $12.02 · Grant/award (A): 62,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Atara Biotherapeutics, Inc. (ATRA) jointly with Adiumentum Capital Fund I LP, Adiumentum Capital Fund I GP LLC | Grant/award (A): 75,572 @ $6.61 · Grant/award (A): 227,000 (derivative) @ $6.61 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=2023732 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →